Specialties

No clear link between comorbidities and risk of PIRA

Presented By

Dr Peter Alping , Karolinska Institutet, Sweden

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:55

Machine learning applied to MRI data can identify MS subtypes

Presented By

Dr Alessia Bianchi, University College London, UK

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:54

Menopause may alter the course of MS

Presented By

Yasemin Şimşek, İzmir University, Turkey

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:53

A 13-protein panel firmly predicts PIRA over the next year

Presented By

Andrea Landwehr , University Hospital Münster, Germany

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:52

Machine learning enables personalised prediction of cognitive decline in MS

Presented By

Dr Elisa Colato , Amsterdam UMC, the Netherlands

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:50

“Give physical and cognitive symptoms equal attention in MS”

Presented By

Prof. Maria Pia Amato , University of Florence, Italy

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:49

Maintenance MOGAD therapy can be safely discontinued

Presented By

Dr Marine Boudot de la Motte , Foundation Hospital Adolphe de Rothschild, France

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:47

Novel anti-CD20 antibody shows efficacy in AQP4-IgG-positive NMOSD

Presented By

Prof. De-hui Huang , Chinese PLA General Hospital, China

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:46

Anti-CD20 therapies outperform platform DMTs in prepubertal MS

Presented By

Dr Riccardo Nistri , University College London, UK

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:45

Ocrelizumab established as a new option for children with MS

Presented By

Prof. Brenda Banwell, Johns Hopkins University, MD, USA

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:43

High intake of ultra-processed food linked to increased MS activity

Presented By

Dr Gloria Dalla Costa , Harvard T.H. Chan School of Public Health, Boston, MA, USA

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:34

Applying the new McDonald criteria increases the rate of MS diagnosis

Presented By

Dr Luca Bollo , Vall Hebron University Hospital, Spain

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:33

High-dose ocrelizumab has no additional benefit in PPMS

Presented By

Prof. Stephen Hauser , University of California, CA, USA

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:32

Nurr1 activation: A novel approach to preventing neurodegeneration in MS

Presented By

Prof. Robert Fox , Cleveland Clinic, OH, USA

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:30

Ocrelizumab delays disability progression in older patients with PPMS

Presented By

Prof. Gavin Giovannoni , Queen Mary University of London, UK

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:29

Live attenuated MMR and varicella vaccines do not increase relapse risk

Presented By

Dr Marta Ponzano , University of Genoa, Italy

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:28

Major shift in France from moderate-efficacy to anti-CD20 therapies

Presented By

Dr Julien Lannoy , CHU Lille, France

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:26

Caution is needed when discontinuing DMT in individuals under 60

Presented By

Dr René Carvajal , Vall Hebron University Hospital, Spain

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:25

Halving the yearly rituximab dose maintains efficacy in RRMS

Presented By

Prof. Anders Svenningsson , Karolinska Institute, Sweden

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:23

Frexalimab shows favourable long-term safety and efficacy

Presented By

Prof. Gavin Giovannoni , Royal London Hospital, UK

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:22

Mesenchymal stem cells show no neuroregenerative benefit in PMS

Presented By

Dr Christopher Elnan Kvistad , Haukeland University Hospital, Norway

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:19

Small remyelinating effect of metformin plus clemastine

Presented By

Dr Nick Cunniffe, University of Cambridge, UK

Conference

ECTRIMS 2025

Type

Peer-reviewed article

25 November 2025 15:17

Mesenchymal stem cells show no neuroregenerative benefit in PMS

Presented By

Dr Christopher Elnan Kvistad , Haukeland University Hospital, Norway

Conference

ECTRIMS 2025

30 September 2025 16:27

Equal impact of high- and moderate-efficacy therapies on PIRMA

Presented By

Dr Laure Michel , Rennes University Hospital, France

Conference

ECTRIMS 2025

30 September 2025 16:25

Novel anti-CD20 antibody shows efficacy in AQP4-IgG-positive NMOSD

Presented By

Prof. De-hui Huang , Chinese PLA General Hospital, China

Conference

ECTRIMS 2025

30 September 2025 16:24

Halving the yearly rituximab dose maintains efficacy in RRMS

Presented By

Prof. Anders Svenningsson , Karolinska Institute, Sweden

Conference

ECTRIMS 2025

30 September 2025 16:21

High-dose ocrelizumab has no additional benefit in PPMS

Presented By

Prof. Stephen Hauser , University of California, CA, USA

Conference

ECTRIMS 2025

30 September 2025 16:13

Menopause may alter the course of MS

Presented By

Yasemin Şimşek , İzmir University, Turkey

Conference

ECTRIMS 2025

29 September 2025 13:58

Machine learning enables personalised prediction of cognitive decline in MS

Presented By

Dr Elisa Colato , Amsterdam UMC, the Netherlands

Conference

ECTRIMS 2025

29 September 2025 13:56

Ocrelizumab established as a new option for children with MS

Presented By

Prof. Brenda Banwell , Johns Hopkins University, MD, USA

Conference

ECTRIMS 2025

29 September 2025 13:55

Small remyelinating effect of metformin plus clemastine

Presented By

Dr Nick Cunniffe, University of Cambridge, UK

Conference

ECTRIMS 2025

29 September 2025 13:53

Ocrelizumab delays disability progression in older patients with PPMS

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Conference

ESCTRIMS 2025

29 September 2025 13:51

Anti-CD20 therapies outperform platform DMTs in prepubertal MS

Presented By

Dr Riccardo Nistri , University College London, UK

Conference

ECTRIMS 2025

26 September 2025 12:43

Live attenuated MMR and varicella vaccines do not increase relapse risk

Presented By

Dr Marta Ponzano , University of Genoa, Italy

Conference

ECTRIMS 2025

26 September 2025 12:42

Caution is needed when discontinuing DMT in individuals under 60

Presented By

Dr René Carvajal , Vall Hebron University Hospital, Spain

Conference

ECTRIMS 2025

26 September 2025 12:39

Applying the new McDonald criteria increases the rate of MS diagnosis

Presented By

Dr Luca Bollo , Vall Hebron University Hospital, Spain

Conference

ECTRIMS 2025

26 September 2025 12:36

Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention

Presented By

Dr Edoardo Caronna , Vall d’Hebron Hospital, Barcelona, Spain

Conference

EAN 2025

26 June 2025 13:19

Rituximab does not halt progression in non-active secondary progressive MS

Presented By

Nadine Ehrhardt , University of Augsburg, Germany

Conference

EAN 2025

26 June 2025 13:16

GLP-1R agonists reduce migraine burden in obese patients

Presented By

Dr Simone Braca, University of Naples, Italy

Conference

EAN 2025

25 June 2025 10:51

Lecanemab in AD: not a paradigm shift, but a small step forward

Presented By

Dr Matilde Bruno, University of Rome Tor Vergata, Italy

Conference

EAN 2025

25 June 2025 10:49

Dementia doubles mortality risk 1 year after hip fracture

Presented By

Prof. Dorota Religa, Karolinska Institutet, Sweden

Conference

EAN 2025

25 June 2025 10:48

Real-world data confirms effectiveness and safety of ofatumumab in MS

Presented By

Dr Gina Ferrazzano, University of Rome Tor Vergata, Italy

Conference

EAN 2025

25 June 2025 10:46

Comparable effectiveness and persistence of ocrelizumab, natalizumab

Presented By

Dr Elena Barbuti, Sapienza University of Rome, Italy

Conference

EAN 2025

24 June 2025 12:28

Why a good result of migraine treatment may not be good enough

Presented By

Dr Edoardo Caronna, Vall d’Hebron University Hospital, Spain

Conference

EAN 2025

24 June 2025 12:27

World MS Day: Interview with Dr Lydia Makaroff

26 May 2025 10:39

AF and dementia: largest Mediterranean cohort reveals age-dependent association

Presented By

Dr Julian Rodríguez-García, Bellvitge University Hospital, Barcelona, Spain

Conference

EHRA 2025

Type

News article

6 May 2025 11:34

Genetic and phenotypic risk model predicts MS

Presented By

Ms Alyks Linerud, Brigham Young University, UT, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:38

Novel AI algorithm better identifies risk factors of MS

Presented By

Dr Zongqi Xia, University of Pittsburgh, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:36

Paramagnetic rim lesions predict effectiveness of tolebrutinib

Presented By

Dr Jiwon Oh, University of Toronto, Canada

Trial

HERCULES, GEMINI

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:34

Atypical and radiological-only presentations often meet 2024 MS criteria

Presented By

Ms Alexandra Scharf, Cleveland Clinic, OH, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:29

Treatment with cladribine tablets: real-world insights

Presented By

Mr Gerard Harty, Merck KGaA, Germany

Trial

CLADRISE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:27

Favourable effectiveness and persistence of cladribine versus other oral DMTs

Presented By

Prof. Helmut Butzkueven, Monash University, Australia

Trial

GLIMPSE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:26

Ofatumumab: good initial adherence and treatment satisfaction

Presented By

Dr Anneke van der Walt, Monash University, Australia

Trial

EAFToS

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:24

MS activity remains low on long-term fenebrutinib

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:22

Higher-dosed ocrelizumab associated with less disability accrual

Presented By

Dr Robert Bermel, Cleveland Clinic, OH, USA

Trial

Phase 3, OPERA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:21

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By

Prof. Michael Dwyer, University at Buffalo, NY, USA

Trial

Phase 3, ORATORIO

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:19

Discontinuing therapy has few risks in patients with MS over 60 years

Presented By

Prof. John Corboy, University of Colorado, CO, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:17

Comorbidity burden associated with risk of adverse events

Presented By

Prof. Amber Salter, UT Southwestern Medical Center, TX, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:15

Update on safety profile of cladribine tablets yields positive results

Presented By

Prof. Thomas Leist, Jefferson University, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:14

Safety of 30-minute ublituximab infusions confirmed

Presented By

Dr John Foley, Rocky Mountain Multiple Sclerosis Center, UT, USA

Trial

ENHANCE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:12

Orelabrutinib highly effective in relapsing-remitting MS, based on MRI results

Presented By

Prof. Yan Xu, Peking Union Medical College Hospital, China

Trial

Phase 2

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:08

Immunomodulatory potential of ketogenic diet in MS confirmed

Presented By

Dr Michael Kornberg, Johns Hopkins University, MD, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:06

A pre-relapse immune signature implicates EBV reactivation in MS relapse

Presented By

Dr Devin King, Brigham and Women’s Hospital, MA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:03

Meet the Trialist: Dr Jiwon Oh

Expert

Dr Jiwon Oh, St Michael’s Hospital, University of Toronto, Canada

Conference

ACTRIMS 2025

5 March 2025 10:59

The locus coeruleus is involved in processing pain in migraine

Presented By

Dr Veronica Munday, King’s College London, UK

Conference

EHC 2024

Type

News article

6 January 2025 11:47

Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura

Presented By

Ms Zi-Rou Jiang, National Yang Ming Chiao Tung University, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:46

AI can enhance migraine diagnosis using easy-to-measure clinical data

Presented By

Dr Antonios Danelakis, Norwegian University of Science and Technology, Norway

Conference

EHC 2024

Type

News article

6 January 2025 11:43

MRI analyses suggest that migraine is not associated with altered brain white matter

Presented By

Dr Cédric Gollion, University Hospital Centre of Toulouse, France

Trial

REFORM

Conference

EHC 2024

Type

News article

6 January 2025 11:39

More education on migraine features is needed

Presented By

Dr Lucas Overeem, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:37

PACAP-targeting therapies: a future option for migraine?

Presented By

Dr Zixuan Alice Zhuang, University of Copenhagen, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:36

Rapid complete responses with atogepant

Presented By

Dr Andreas Gantenbein, Zurzach Care, Switzerland

Trial

Phase 3, ADVANCE, ELEVATE, PROGRESS

Conference

EHC 2024

Type

News article

6 January 2025 11:35

Cabergoline is a potential add-on treatment option in patients with migraine

Presented By

Dr Astrid Hjelholt, Aarhus University Hospital, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:32

Nitroglycerin-induced migraine targetable by different agents

Presented By

Dr Charlotte Ernstsen Lauritzen, H. Lundbeck A/S, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:31

Rimegepant reduces migraine symptoms through 1 year of treatment

Presented By

Dr Shengyuan Yu, PLA General Hospital, China

Trial

Phase 2

Conference

EHC 2024

Type

News article

6 January 2025 11:29

Fremanezumab is a treatment option for paediatric patients with episodic migraine

Presented By

Prof. Patricia Pozo-Rosich, Vall d’Hebron Institute of Research, Spain

Trial

Phase 3, SPACE-EM

Conference

EHC 2024

Type

News article

6 January 2025 11:27

What brain changes are associated with fremanezumab treatment success?

Presented By

Prof. Ángel Guerrero, University of Valladolid, Spain

Trial

FreMRI

Conference

EHC 2024

Type

News article

6 January 2025 11:25

Low discontinuation rates with preventative galcanezumab in a real-world setting

Presented By

Dr Sait Ashina, Harvard Medical School, MA, USA

Trial

TRIUMPH

Conference

EHC 2024

Type

News article

6 January 2025 11:23

Biofeedback training can reduce affected days in episodic migraine

Presented By

Dr Amalie Christine Poole, Norwegian University of Science and Technology, Norway

Trial

BioCer

Conference

EHC 2024

Type

News article

6 January 2025 11:20

Virtual reality interventions can reduce pain perception of chronic headache

Presented By

Prof. Sara Bottiroli, University of Pavia, Pavia, Italy

Conference

EHC 2024

Type

News article

6 January 2025 11:18

Can predisposing factors be targeted to reduce new migraine incidence?

Presented By

Ms Maria Terhart, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:15

Active migraine comes at a high cost in Spain

Presented By

Dr Margarita Sánchez del Río, Clinica Universidad de Navarra, Spain

Conference

EHC 2024

Type

News article

6 January 2025 11:13

Many patients, including non-responders, prefer triptans over non-headache-specific medication

Presented By

Dr Arne Hostens, Free University of Brussels, Belgium

Conference

EHC 2024

Type

News article

6 January 2025 11:12

DPP-4 is better target to lower migraine rates in patients with type 2 diabetes

Presented By

Dr Chen Ting-Chuan, Taichung Veterans General Hospital, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:10

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments

Presented By

Ms Deirdre Boucherie, Erasmus University Medical Centre Rotterdam, the Netherlands

Conference

EHC 2024

Type

News article

6 January 2025 11:08

Revised McDonald criteria allow earlier and more precise MS diagnosis

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:52

Approaches to RIS and MS converge

Presented By

Prof. Christine Lebrun-Frénay, Centre Hospitalier Universitaire de Nice, France

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:50

AI versus clinicians: who diagnoses MS faster and better?

Presented By

Ms Mahi Patel, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:47

Blood markers predict MS progression

Presented By

Dr Ahmed Abdelhak, University of California San Francisco, CA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:46

Gut microbiota modulate inflammation and cortical damage

Presented By

Dr Federico Montini, Brigham and Women's Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:43

Risk factors and importance of persistent PIRA

Presented By

Dr Chao Zhu, Monash University, Australia

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:39

Vitamin D supplementation in progressive MS should be medically supervised

Presented By

Dr Michaela Haindl, Medical University of Graz, Austria

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:38

Encouraging real-world results of AHSCT to treat aggressive MS

Presented By

Prof. Paolo Muraro, London Bridge Hospital, UK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:35

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By

Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:33

B cell-tailored dosing of ocrelizumab shows good results

Presented By

Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands

Trial

BLOOMS

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:28

Risk associated with discontinuing therapy depends on specific drug

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:26

First-line moderate-efficacy DMTs show similar efficacy

Presented By

Dr Clara López-Caneda, Hospital Alvaro Cunqueiro, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:23

Tolebrutinib slows disability worsening in relapsing MS

Presented By

Dr Jiwon Oh, St. Michael's Hospital, Canada

Trial

Phase 3, GEMINI 1, GEMINI 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:21

Frexalimab shows favourable safety and efficacy in OLE

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:17

Good safety of ozanimod over up to 8 years of treatment

Presented By

Prof. Krzysztof Selmaj, University of Warmia and Mazury, Poland

Trial

DAYBREAK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:16

Tolebrutinib slows disability in non-relapsing SPMS

Presented By

Prof. Robert Fox, Cleveland Clinic, OH, USA

Trial

Phase 3, HERCULES

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:13